See L-Carnitine dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
L-Carnitine (levocarnitine) is a quaternary ammonium compound essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase shuttle, and is FDA-approved as Carnitor for primary and secondary carnitine deficiency. It has an extensive clinical literature in dialysis, cardiovascular disease, and exercise performance, and is widely used off-label in metabolic and weight-loss clinics. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with L-Carnitine.
L-Carnitine (international name levocarnitine) is a quaternary ammonium compound synthesized endogenously from lysine and methionine and obtained additionally through dietary intake (primarily red meat). Its biological role is unusually well-defined: it is the obligate substrate for the carnitine palmitoyltransferase 1 and 2 (CPT-1 / CPT-2) shuttle that transports long-chain fatty acyl-CoA molecules across the inner mitochondrial membrane, where they enter beta-oxidation and become available for ATP generation.
L-carnitine (levocarnitine) is a naturally occurring nutrient that helps transport fatty acids into mitochondria for energy, most often sourced for fat-metabolism and exercise research. It is FDA-approved as Carnitor for carnitine deficiency and is widely used in sports nutrition. It is supplied in several forms — injectable solution, capsules, or powder.
L-carnitine is the substrate for the carnitine-palmitoyltransferase (CPT) shuttle: long-chain acyl-CoA is converted to acyl-carnitine by CPT1 on the outer mitochondrial membrane, transported across the inner membrane via the carnitine-acylcarnitine translocase, and reconverted to acyl-CoA by CPT2 in the matrix for β-oxidation. Without adequate tissue carnitine, long-chain fatty acid oxidation cannot proceed efficiently. The acetyl-L-carnitine variant has additional CNS-active properties as a methyl donor and acetylcholine precursor.
FDA-approved indications include primary carnitine deficiency (a rare inborn error of metabolism) and secondary carnitine deficiency in end-stage renal disease patients on hemodialysis. Off-label research areas include cardiac ischemia, peripheral arterial disease (intermittent claudication, where propionyl-L-carnitine has the strongest evidence base), male infertility, exercise performance, and fat oxidation. The Stephens / Brass body of work establishes that meaningful changes in muscle carnitine content require sustained insulin co-administration (carbohydrate), not bolus injection alone.
L-Carnitine has a reported half-life of ~15 hours, and the dose intervals researchers model most often fall around once daily. A roughly half-day half-life means daily dosing tops up a partially-retained pool, with modest buildup toward a stable level over a few days. It is catalogued under Weight Loss on WPA.
56 L-Carnitine reconstitution calculations have been logged by the WPA community. The most common dose entered is 50mg (14 calculations). The median dose across all sessions is 60mg. The most common bacteriostatic water volume is 10mL. The most popular vial size is 500mg (18 sessions). The most common dosing frequency is daily (7x/week) (1 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.